HUP0300332A2 - Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítmények - Google Patents

Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0300332A2
HUP0300332A2 HU0300332A HUP0300332A HUP0300332A2 HU P0300332 A2 HUP0300332 A2 HU P0300332A2 HU 0300332 A HU0300332 A HU 0300332A HU P0300332 A HUP0300332 A HU P0300332A HU P0300332 A2 HUP0300332 A2 HU P0300332A2
Authority
HU
Hungary
Prior art keywords
solvate
pharmaceutically acceptable
acceptable salt
salt
betablocker
Prior art date
Application number
HU0300332A
Other languages
English (en)
Inventor
Göran Bondjers
Olov Wiklund
John Wikstrand
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0001188A external-priority patent/SE0001188D0/xx
Priority claimed from SE0002352A external-priority patent/SE0002352D0/xx
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0300332A2 publication Critical patent/HUP0300332A2/hu
Publication of HUP0300332A3 publication Critical patent/HUP0300332A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya b-blokkoló szert és HMG-CoA reduktáz inhibitorttartalmazó gyógyszerkombináció, amely b-blokkoló szerként acebutololt,alprenololt, amosulalolt, arotinololt, atenololt, befunololt,betaxololt, bevantololt, bisoprololt, bopindololt, bukumololt,bufetololt, bufuralolt, bunitrololt, buprandololt, butofilololt,karazololt, karteololt, karvedilolt, celiprololt, cetamololt,klorandololt, dilevalolt, epanololt, indenololt, labetalolt,levobunololt, mepindololt, metipranololt, metoprololt, moprololt,nadololt, nadoxololt, nebivalolt, nipradilolt, oxprenololt,perbutololt, pindololt, praktololt, pronetalolt, propranololt,szotalolt, szufinalolt, talindolt, tertalololt, tiliszololt, timololt,toliprololt, xibenololt, vagy bármelyikük gyógyászatilag alkalmazhatósóját vagy szolvátját vagy a gyógyászatilag alkalmazható sószolvátját, míg HMG-CoA reduktáz inhibitorként cerivasztatint,itavasztatint, lovasztatint, mevasztatint, nikosztatint, nivasztatint,(E)-7-[4-(4-fluor-fenil)-6-izopropil-2-(metil-/metilszulfonil/-amino)-pirimidin-5-il]-(3R,5S)-3,5-dihidro-hept-6-én-karbonsavat, vagybármelyikük gyógyászatilag alkalmazható sóját vagy szolvátját vagy agyógyászatilag alkalmazható só szolvátját tartalmazza. Ó
HU0300332A 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them HUP0300332A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001188A SE0001188D0 (sv) 2000-04-03 2000-04-03 New combination
SE0002352A SE0002352D0 (sv) 2000-06-22 2000-06-22 New combination
PCT/SE2001/000663 WO2001074394A1 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent

Publications (2)

Publication Number Publication Date
HUP0300332A2 true HUP0300332A2 (hu) 2003-06-28
HUP0300332A3 HUP0300332A3 (en) 2005-03-29

Family

ID=26655059

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300332A HUP0300332A3 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them

Country Status (25)

Country Link
US (2) US20030060477A1 (hu)
EP (1) EP1272219B1 (hu)
JP (1) JP2003528928A (hu)
KR (1) KR20020086749A (hu)
CN (1) CN1422161A (hu)
AR (1) AR030414A1 (hu)
AT (1) ATE347909T1 (hu)
AU (2) AU4298501A (hu)
BR (1) BR0109753A (hu)
CA (1) CA2403160A1 (hu)
DE (1) DE60125159T2 (hu)
EE (1) EE200200570A (hu)
ES (1) ES2276774T3 (hu)
HK (1) HK1051325A1 (hu)
HU (1) HUP0300332A3 (hu)
IL (1) IL151589A0 (hu)
IS (1) IS6554A (hu)
MX (1) MXPA02009705A (hu)
MY (1) MY136386A (hu)
NO (1) NO20024732D0 (hu)
NZ (1) NZ521351A (hu)
PL (1) PL357813A1 (hu)
RU (1) RU2002123591A (hu)
SK (1) SK14102002A3 (hu)
WO (1) WO2001074394A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ITMI20040145A1 (it) * 2004-01-30 2004-04-30 Acraf L-moprololo lpiu' tartrato
EP1722758A1 (en) * 2004-02-11 2006-11-22 Athpharma Limited Chronotherapeutic compositions and methods of their use
WO2005110985A2 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (sarms)
CN101022791B (zh) * 2004-06-04 2011-11-16 麦兰实验室公司 含奈必洛尔的组合物
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 HMG-CoA 환원 효소 억제제의 신규 복합 조성물
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
CN102462844A (zh) * 2010-11-05 2012-05-23 四川滇虹医药开发有限公司 一种替利洛尔的药物组合物及其制备方法
WO2013157833A1 (ko) * 2012-04-18 2013-10-24 서울대학교산학협력단 베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물
CN103613586B (zh) * 2013-11-01 2016-06-08 北京博爱旺康医药科技有限公司 一种旋光纯s-(-)-阿罗洛尔酸式盐及其制备方法和应用
CN103626750B (zh) * 2013-11-15 2016-02-24 北京博爱旺康医药科技有限公司 一种盐酸阿罗洛尔及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
EP0576617B1 (en) * 1991-03-18 1996-08-07 Sepracor, Inc. Composition and method containing optically pure (s) metoprolol
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
ATE248606T1 (de) * 1998-12-23 2003-09-15 Searle Llc Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Also Published As

Publication number Publication date
NZ521351A (en) 2004-08-27
HUP0300332A3 (en) 2005-03-29
JP2003528928A (ja) 2003-09-30
WO2001074394A1 (en) 2001-10-11
AU4298501A (en) 2001-10-15
RU2002123591A (ru) 2004-03-20
EP1272219B1 (en) 2006-12-13
CA2403160A1 (en) 2001-10-11
PL357813A1 (en) 2004-07-26
AR030414A1 (es) 2003-08-20
EE200200570A (et) 2004-04-15
NO20024732L (no) 2002-10-02
HK1051325A1 (en) 2003-08-01
MXPA02009705A (es) 2004-02-26
KR20020086749A (ko) 2002-11-18
MY136386A (en) 2008-09-30
SK14102002A3 (sk) 2003-06-03
IL151589A0 (en) 2003-04-10
NO20024732D0 (no) 2002-10-02
ES2276774T3 (es) 2007-07-01
US20030060477A1 (en) 2003-03-27
AU2001242985B2 (en) 2005-02-24
EP1272219A1 (en) 2003-01-08
DE60125159D1 (de) 2007-01-25
CN1422161A (zh) 2003-06-04
ATE347909T1 (de) 2007-01-15
DE60125159T2 (de) 2007-10-25
IS6554A (is) 2002-09-19
BR0109753A (pt) 2003-02-04
US20040192784A1 (en) 2004-09-30
WO2001074394A8 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
HUP0300332A2 (hu) Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítmények
JP2001523710A5 (hu)
NO20020968L (no) Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
DE69937691D1 (de) Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
KR970705990A (ko) 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
JP2004511435A5 (hu)
WO2005009431B1 (en) Methods for treating inflammation and inflammation-associated diseases with a statin and ether
EP1251846A4 (en) TAXANE WITH CARBONATES IN C-4
NO20041060L (no) Krystaller av hydroksynorefedrinderivat
JP2002508320A5 (hu)
NO980395D0 (no) Naftyl og dihydronaftyl mellomprodukter, forbindelser, sammensetninger og metoder
Hu et al. Peptidyl hydroxamic acids as methionine aminopeptidase inhibitors
CY1109546T1 (el) Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας
PT1150667E (pt) Alcool de cadeia longa de ciclo-hexenona para tratamento de esclerose amiotrofica lateral
AU2003220958A1 (en) Remedies for glomerular diseases
EP1275388A4 (en) TNF ALPHA INHIBITORS
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
DE60121695D1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
GB2371748A (en) HMG-COA reductase inhibitor extended release formulation
HUP0105019A2 (hu) Egy koleszterinszint-csökkentő szer felhasználása
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
US20100286125A1 (en) Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
JPWO2004091660A1 (ja) Lklf/klf2遺伝子発現促進剤
EP1296716B1 (en) Use of a beta-blocker for the treatment of atherosclerosis
BR0210426A (pt) Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo